Navigation Links
OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013
Date:10/30/2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 30, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2013 financial results will be released on Thursday, November 7, 2013, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results and will address frequently asked questions from investors.

"For this quarter's call, we are evaluating a new format in order to address questions submitted via our website and other channels. The discussion will include recent inquiries regarding the prostate cancer market landscape and our clinical development program," stated Scott Cormack, President and CEO of OncoGenex. "While we remain blinded to the SYNERGY and Borealis-1 data, we will review the estimated timelines, which remain unchanged from those disclosed in our quarterly report on Form 10-Q for the second quarter of 2013."  

Questions can be submitted via email to investor-relations@oncogenex.com. Those received before noon Pacific/3:00 p.m. Eastern on Thursday, Nov. 7, will be considered for the discussion.

  • To access the webcast, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com. Alternatively, you may access the live conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days. You can also monitor key information from the quarterly call by following the new OncoGenex Investor Relations Twitter account at: http://twitter.com/@OncoGenex_IR

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our expected timelines for our SYNERGY and Borealis-1 trials. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that our product candidates will not demonstrate the hypothesized or expected benefits, the risk of delays in our expected clinical trials and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
2. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
4. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
5. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
6. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
8. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
9. Hanger Reports Third Quarter 2013 Results
10. Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
11. Questcor Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , January 23, 2017 Longer life expectancy and ... the global market for medical device technologies. BCC Research reveals ... Asia-Pacific region, should see strong growth due to ... disposable incomes. Continue Reading ... ...
(Date:1/23/2017)... 2017  ResMed (NYSE : RMD), BMC (Pékin, Chine) et ... aujourd,hui qu,ils se sont mis d,accord sur le règlement ... BMC et 3B seront autorisés à vendre leurs produits ... et ResMed effectuera le paiement de la décision en ... de Floride entre les deux parties. Le règlement n,inclut ...
(Date:1/23/2017)... Spain , January 23, 2017 /PRNewswire/ ... biopharmaceutical company focused on treatments for calcification disorders, ... enrolled in the Phase IIb "CaLIPSO Study" clinical ... of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients ... in the last stage of chronic kidney disease, ...
Breaking Medicine Technology:
(Date:1/23/2017)... , ... January 23, 2017 , ... ... high-quality general gynecological care and gynecological services for women of all ... care for a wide variety of reproductive services from routine health screenings to ...
(Date:1/23/2017)... ... ... “Crossing the Bar”: a moving and eloquent drama depicting the events that happen ... creation of published author, Charlotte Hotte, a North Carolina native, a mother of two, ... book to her sister, Denise, wishes to acknowledge her savior, Jesus Christ, along with ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: ... from an early age. “Life Under Blankets” is the creation of published author, Kimberly ... Circle Campus in Chicago. She went on to pursue a master’s degree in education ...
(Date:1/23/2017)... ... ... Day is a time when many people celebrate romance and love by giving cards, candy, ... the ideal present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day special: ... and get $50 free. , “A lot of people just buy the more predictable ...
(Date:1/22/2017)... ... 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing a unique ... buyers at the January ECRM Trade Show in Hilton Head, SC. , Zifam Pinnacle ... in all of its creations to help create a more traditional and natural approach ...
Breaking Medicine News(10 mins):